YIDU TECH (02158) rose over 6% in late trading. As of the time of writing, the stock was up 5.69%, trading at HK$5.94, with a turnover of HK$74.3717 million. Recently, the "Beijing Key Laboratory for Research and Development and Translational Application of Multimodal Intelligent Diagnosis and Treatment Systems," jointly established by Peking University First Hospital as the lead institution with participation from YIDU TECH, was successfully approved. The laboratory will focus on intelligent diagnosis and treatment breakthroughs for cardio-renal metabolic syndrome, marking another critical milestone in YIDU TECH's sustained, deep cultivation of specialized intelligent diagnostics. As a core co-builder of the laboratory, YIDU TECH will deeply integrate its large model technology capabilities into the lab's R&D pipeline, providing a solid foundation for the practical implementation of intelligent diagnosis and treatment. Currently, the development of medical artificial intelligence has fully entered the value-validation phase centered on "practical application." The establishment of this laboratory is a typical example of the deeply integrated and collaborative innovation model combining industry, academia, research, and medicine. YIDU TECH has already partnered with several renowned domestic hospitals to establish joint laboratories, supporting the research blueprint from data governance to model development, and from system construction to成果转化 (achievement translation), ensuring a solid and efficient path to implementation with its full-stack technical capabilities.
Comments